Skip to main content

Table 2 Mean live Rhipicephalus sanguineus sensu lato counts and efficacy relative to placebo at 12 hours after treatment and post-treatment re-infestations for dogs treated with a single oral dose of either sarolaner or afoxolaner on Day 01

From: Comparative speed of kill of sarolaner (Simparica™) and afoxolaner (NexGard®) against induced infestations of Rhipicephalus sanguineus s.l. on dogs

Treatment   Day of treatment or re-infestation
  0 7 14 21 28 35
Placebo Range 17–42 20–38 15–40 19–40 27–40 25–41
A. mean 28.6 30.5 30.9 31.9 34.4 32.1
G. mean2 27.5a 29.6a 29.8a 31.1a 34.2a 31.8a
Sarolaner Range 0–2 8–27 13–25 22–31 15–31 20–38
A. mean 0.3 20.0 19.8 24.9 24.6 27.3
Efficacy (%) 99.1 34.4 36.0 22.0 28.4 15.2
G. mean2 0.1b 18.9b 19.1b 24.7a 24.2b 26.7a
Efficacy (%) 99.5 36.1 35.9 20.5 29.2 15.9
P-value vs. placebo <0.0001 0.0142 0.0061 0.0754 0.0020 0.0715
Afoxolaner Range 0–5 26–42 16–34 23–36 25–33 23–35
A. mean 2.4 34.4 26.3 29.9 29.9 30.7
Efficacy (%) 91.5 0.0 14.9 6.3 13.1 4.4
G. mean2 1.7c 33.9a 25.5a,b 29.4a 29.7a 30.5a
Efficacy (%) 93.8 0.0 14.6 5.5 13.0 4.1
P-value vs. placebo <0.0001 0.3251 0.3213 0.6858 0.0553 0.6435
P-value vs. sarolaner 0.0286 0.0015 0.0732 0.0770 0.0463 0.1679
  1. 1 n = 7 for afoxolaner, n = 8 for placebo and sarolaner groups
  2. 2Geometric means within columns with the same superscript are not significantly different (P > 0.05)